GAITHERSBURG, Md. (MedPage Today) — An FDA advisory panel was divided over whether to recommend the approval of the investigational weight-loss drug phentermine/topiramate (Qnexa), but the Nay votes prevailed 10-6. (Source: MedPage Today Public Health)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and re ceive $5 free advertising.
Title: ‘Female Viagra‘ Is Rejected by FDA PanelCategory: Health NewsCreated: 6/21/2010 10:59:00 AMLast Editorial Review: 6/21/2010 10:59:18 AM (Source: MedicineNet Senior Health General)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.
Title: ‘Female Viagra‘ Is Rejected by FDA PanelCategory: Health NewsCreated: 6/21/2010 10:59:00 AMLast Editorial Review: 6/21/2010 10:59:18 AM (Source: MedicineNet Mens Health General)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.
Title: ‘Female Viagra‘ Is Rejected by FDA PanelCategory: Health NewsCreated: 6/21/2010 10:59:00 AMLast Editorial Review: 6/21/2010 10:59:18 AM (Source: MedicineNet Depression General)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.
WASHINGTON (MedPage Today) — The investigational drug that has been dubbed the “female Viagra” will come under scrutiny tomorrow by an FDA advisory panel. (Source: MedPage Today Public Health)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.
Title: ‘Female Viagra‘ Is Rejected by FDA PanelCategory: Health NewsCreated: 6/21/2010 10:59:00 AMLast Editorial Review: 6/21/2010 10:59:18 AM (Source: MedicineNet Menopause General)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.
On Friday, an FDA advisory panel voted 11-0 against recommending FDA approval of a proposed treatment for hypoactive sexual-desire disorder, which decreases women’s sex drive, the Wall Street Journal reports. The R eproductive Health Drugs Advisory Committee reviewed an application seeking FDA approval of the drug flibanserin, also known as the “pink pill” or “female Viagra.” Although the agency is not required to follow the panel’s recommendation, (more…)
WASHINGTON (MedPage Today) — The U.S. Senate voted to delay a steep pay cut for doctors, but not before CMS began processing claims at the lower rate, an FDA panel approved a new morning-after pill and voted against “female Viagra“, and the agency fined the Red Cross for blood safety violations. (Source: MedPage Today Public Health)
GAITHERSBURG, Md. (MedPage Today) — An FDA advisory committee has decided that the makers of the investigational drug flibanserin (Girosa) — often dubbed the female Viagra — haven’t proved that the pill treats hypoactive sexual-desire disorder (HSDD) in women any better than placebo. (Source: MedPage Today P roduct Alert)
On June 18, FDA’s Reproductive Health Drugs Advisory Committee will consider the first pill aimed at improving women’s sexual desire though alteration of brain chemicals, the Washington Post reports. The prospect of a so-called “female Viagra” has sparked debate over w hether the drug — Germany-based Boehringer Ingelheim’s flibanserin — represents progress toward women’s health equality or a pharmaceutical industry ploy… (Source: Health News (more…)